Literature DB >> 7513071

Organ-specific autoantigens induce interferon-gamma and interleukin-4 mRNA expression in mononuclear cells in multiple sclerosis and myasthenia gravis.

J Link1, M Söderström, A Ljungdahl, B Höjeberg, T Olsson, Z Xu, S Fredrikson, Z Y Wang, H Link.   

Abstract

T cells recognizing the myelin components myelin basic protein (MBP) and proteolipid protein (PLP) are increased in multiple sclerosis (MS), and there are elevated numbers of T cells recognizing the nicotinic acetylcholine receptor (AChR) in myasthenia gravis (MG). However, the cytokine repertoires in these diseases are largely unknown. We adopted in situ hybridization with radiolabeled complementary DNA oligonucleotide probes to enumerate mononuclear cells that expressed the T-helper type 1 (Th1) cell-related interferon-gamma (IFN-gamma) and Th2-associated interleukin-4 (IL-4) after short-term culture in the presence of autoantigen. High numbers of IFN-gamma and IL-4 mRNA-expressing cells in response to MBP and PLP were detected in patients with untreated MS, and to AChR in MG. The levels of IFN-gamma and IL-4 mRNA-positive cells in MS after culture in the presence of AChR, and in MG after culture in the presence of MBP or PLP, did not differ from those detected after culture without antigen. The CSF of MS patients contained four- to eightfold more myelin protein-reactive IFN-gamma and IL-4 expressing cells. The findings imply that MS and MG are associated with mixed Th1- and Th2-like cell responses directed to organ-specific target antigens.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513071     DOI: 10.1212/wnl.44.4.728

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  10 in total

1.  Modulation of immune responses and suppression of experimental autoimmune myasthenia gravis by surgical denervation of the spleen.

Authors:  M Bakhiet; L-Y Yu; V Ozenci; A Khan; F-D Shi
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Specific immunotherapy of experimental myasthenia gravis by a novel mechanism.

Authors:  Jie Luo; Alexander Kuryatov; Jon M Lindstrom
Journal:  Ann Neurol       Date:  2010-04       Impact factor: 10.422

Review 3.  Myasthenia gravis as a prototype autoimmune receptor disease.

Authors:  A C Hoedemaekers; P J van Breda Vriesman; M H De Baets
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

4.  Abnormal cytokine profiles in patients with idiopathic dilated cardiomyopathy and their asymptomatic relatives.

Authors:  J B Marriott; J H Goldman; P J Keeling; M K Baig; A G Dalgleish; W J McKenna
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

5.  Matrix metalloproteinase and cytokine profiles in monocytes over the course of stroke.

Authors:  M Kouwenhoven; C Carlström; V Ozenci; H Link
Journal:  J Clin Immunol       Date:  2001-09       Impact factor: 8.317

6.  Nasal tolerance in experimental autoimmune myasthenia gravis (EAMG): induction of protective tolerance in primed animals.

Authors:  F D Shi; X F Bai; H L Li; Y M Huang; P H Van der Meide; H Link
Journal:  Clin Exp Immunol       Date:  1998-03       Impact factor: 4.330

7.  High numbers of autoantigen-reactive mononuclear cells expressing interferon-gamma (IFN-gamma), IL-4 and transforming growth factor-beta (TGF-beta) are present in cord blood.

Authors:  M Yu; S Fredrikson; J Link; H Link
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

8.  Soluble E-selectin in multiple sclerosis: raised concentrations in patients with primary progressive disease.

Authors:  G Giovannoni; J W Thorpe; D Kidd; B E Kendall; I F Moseley; A J Thompson; G Keir; D H Miller; M Feldmann; E J Thompson
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-01       Impact factor: 10.154

9.  Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis.

Authors:  G X Zhang; B G Xiao; M Bakhiet; P van der Meide; H Wigzell; H Link; T Olsson
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

10.  Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK.

Authors:  Vuslat Yilmaz; Piraye Oflazer; Fikret Aysal; Hacer Durmus; Kostas Poulas; Sibel P Yentur; Yesim Gulsen-Parman; Socrates Tzartos; Alexander Marx; Erdem Tuzun; Feza Deymeer; Güher Saruhan-Direskeneli
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.